BDTX (Black Diamond Therapeutics) ROCE %: -36.66% (As of Mar. 2026)


BDTX Black Diamond Therapeutics Inc BDTX
38 GF Score
Price $1.71
! 2 Warning Signs
View Full Analysis

What is Black Diamond Therapeutics ROCE %?

Black Diamond Therapeutics BDTX +0.59% 38 ROCE % is -36.66% as of Mar. 2026. GuruFocus rates BDTX with a GF Score™ of 38/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Black Diamond Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -36.66%.

Black Diamond Therapeutics  (NAS:BDTX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Black Diamond Therapeutics ROCE % Related Terms

Black Diamond Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Black Diamond Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Black Diamond Therapeutics ROCE % Chart

Black Diamond Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only -47.03 -50.86 -61.78 -65.38 17.33

Black Diamond Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 166.84 -34.75 -30.10 -30.47 -36.66
BDTX
38GF Score
Black Diamond Therapeutics Inc BDTX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Black Diamond Therapeutics ROCE % Calculation

Black Diamond Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=19.87/( ( (122.64 - 20.573) + (143.01 - 15.731) )/ 2 )
=19.87/( (102.067+127.279)/ 2 )
=19.87/114.673
=17.33 %

Black Diamond Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-45.036/( ( (143.01 - 15.731) + (132.922 - 14.534) )/ 2 )
=-45.036/( ( 127.279 + 118.388 )/ 2 )
=-45.036/122.8335
=-36.66 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -36.66% mean?
Black Diamond Therapeutics (BDTX) has a ROCE % of -36.66% as of Mar. 2026.
Is Black Diamond Therapeutics' ROCE % too high?
Black Diamond Therapeutics' current ROCE % is -36.66%. Overall, Black Diamond Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Black Diamond Therapeutics' ROCE % compare to GUTS and ALPS?
Black Diamond Therapeutics' ROCE % of -36.66% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Black Diamond Therapeutics's current ROCE % is -36.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Black Diamond Therapeutics stock overvalued right now?
Black Diamond Therapeutics (BDTX) has a current ROCE % of -36.66%. The current ROCE % is -36.66%. Black Diamond Therapeutics' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Black Diamond Therapeutics (BDTX), the current ROCE % is -36.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Black Diamond Therapeutics Business Description

Address 245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
38GF Score

Get the complete analysis for BDTX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price